Cover Image
市場調查報告書

復發性惡性神經膠質瘤:全球臨床實驗檢討

Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015

出版商 GlobalData 商品編碼 299733
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
復發性惡性神經膠質瘤:全球臨床實驗檢討 Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015
出版日期: 2015年02月18日 內容資訊: 英文 93 Pages
簡介

本報告提供復發性惡性神經膠質瘤相關臨床研究最新趨勢相關分析,以疾病概要為首,提供地區及主要國家的臨床實驗狀況,Phase別·各進展狀況臨床實驗資料,被實驗者的募集情況,有潛力的贊助商,並彙整各企業·研究機關臨床實驗簡介等資訊,為您概述為以下內容。

目錄

簡介

  • 復發性惡性神經膠質瘤
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數和平均實驗人數
    • 亞太地區的主要國家
    • 歐洲的主要5個國家
    • 北美的主要國家
    • 中東非洲的主要國家
    • 中南美的主要國家

在G7各國臨床實驗

在G7各國臨床實驗:Phase別

在G7各國臨床實驗:各進展狀況

在E7各國臨床實驗

在E7各國臨床實驗:Phase別

在E7各國臨床實驗:各進展狀況

Phase別臨床實驗

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗

一定期間所採用的實驗對象

贊助商的不同種類的臨床實驗

有潛力的贊助商

  • 參加復發性惡性神經膠質瘤治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Insys Therapeutics, Inc.
    • Merck & Co., Inc.
    • Eisai
    • TransMolecular, Inc.
    • Eli Lilly and Company
    • to-BBB technologies BV
    • Tactical Therapeutics, Inc
    • Shandong Lanjin Pharmaceuticals Co. Ltd
    • Direct Therapeutics, Inc.
    • Amgen Inc.
  • 有代表性的醫院·研究機關臨床實驗概要
    • National Cancer Institute
    • Duke University
    • Memorial Sloan Kettering Cancer Center
    • North American Brain Tumor Consortium
    • The University of Texas M. D. Anderson Cancer Center
    • Northwestern University
    • UCLA's Jonsson Comprehensive Cancer Center
    • Sidney Kimmel Comprehensive Cancer Center
    • University of Colorado
    • Wake Forest University

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC2563CTIDB

GlobalData's clinical trial report, "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Recurrent Malignant Glioma
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Recurrent Malignant Glioma
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • INSYS Therapeutics, Inc.
      • Clinical Trial Overview of INSYS Therapeutics, Inc.
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • Eisai Co., Ltd.
      • Clinical Trial Overview of Eisai Co., Ltd.
      • TransMolecular, Inc.
      • Clinical Trial Overview of TransMolecular, Inc.
      • Tactical Therapeutics, Inc
      • Clinical Trial Overview of Tactical Therapeutics, Inc
      • Shandong Lanjin Pharmaceuticals Co. Ltd
      • Clinical Trial Overview of Shandong Lanjin Pharmaceuticals Co. Ltd
      • Oncolytics Biotech Inc.
      • Clinical Trial Overview of Oncolytics Biotech Inc.
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • Alkermes Plc
      • Clinical Trial Overview of Alkermes Plc
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Duke University
      • Clinical Trial Overview of Duke University
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • North American Brain Tumor Consortium
      • Clinical Trial Overview of North American Brain Tumor Consortium
      • University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of University of Texas M. D. Anderson Cancer Center
      • Northwestern University
      • Clinical Trial Overview of Northwestern University
      • UCLA's Jonsson Comprehensive Cancer Center
      • Clinical Trial Overview of UCLA's Jonsson Comprehensive Cancer Center
      • City of Hope
      • Clinical Trial Overview of City of Hope
      • University of Colorado
      • Clinical Trial Overview of University of Colorado
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2015*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2015*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Suspended Clinical Trials, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by INSYS Therapeutics, Inc., 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by TransMolecular, Inc., 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Tactical Therapeutics, Inc, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Shandong Lanjin Pharmaceuticals Co. Ltd, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncolytics Biotech Inc., 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Alkermes Plc, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by North American Brain Tumor Consortium, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas M. D. Anderson Cancer Center, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by UCLA's Jonsson Comprehensive Cancer Center, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Colorado, 2015*

List of Figures

  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2015*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2015*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top